KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Travere Therapeutics (TVTX) over the last 13 years, with Q3 2025 value amounting to $11.3 million.

  • Travere Therapeutics' Share-based Compensation rose 4040.14% to $11.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $42.6 million, marking a year-over-year increase of 1890.19%. This contributed to the annual value of $36.9 million for FY2024, which is 1657.32% down from last year.
  • Latest data reveals that Travere Therapeutics reported Share-based Compensation of $11.3 million as of Q3 2025, which was up 4040.14% from $10.6 million recorded in Q2 2025.
  • Over the past 5 years, Travere Therapeutics' Share-based Compensation peaked at $13.5 million during Q1 2023, and registered a low of $7.0 million during Q3 2021.
  • Its 5-year average for Share-based Compensation is $9.6 million, with a median of $9.3 million in 2022.
  • Per our database at Business Quant, Travere Therapeutics' Share-based Compensation surged by 7320.45% in 2022 and then crashed by 2914.05% in 2024.
  • Quarter analysis of 5 years shows Travere Therapeutics' Share-based Compensation stood at $7.4 million in 2021, then increased by 26.04% to $9.3 million in 2022, then dropped by 12.4% to $8.1 million in 2023, then rose by 13.14% to $9.2 million in 2024, then rose by 22.24% to $11.3 million in 2025.
  • Its Share-based Compensation was $11.3 million in Q3 2025, compared to $10.6 million in Q2 2025 and $11.5 million in Q1 2025.